Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Imaging activated T cells predicts response to cancer vaccines.

Alam IS, Mayer AT, Sagiv-Barfi I, Wang K, Vermesh O, Czerwinski DK, Johnson EM, James ML, Levy R, Gambhir SS.

J Clin Invest. 2018 Jun 1;128(6):2569-2580. doi: 10.1172/JCI98509. Epub 2018 May 14.

2.

Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo.

Kooreman NG, Kim Y, de Almeida PE, Termglinchan V, Diecke S, Shao NY, Wei TT, Yi H, Dey D, Nelakanti R, Brouwer TP, Paik DT, Sagiv-Barfi I, Han A, Quax PHA, Hamming JF, Levy R, Davis MM, Wu JC.

Cell Stem Cell. 2018 Apr 5;22(4):501-513.e7. doi: 10.1016/j.stem.2018.01.016. Epub 2018 Feb 15.

PMID:
29456158
3.

Eradication of spontaneous malignancy by local immunotherapy.

Sagiv-Barfi I, Czerwinski DK, Levy S, Alam IS, Mayer AT, Gambhir SS, Levy R.

Sci Transl Med. 2018 Jan 31;10(426). pii: eaan4488. doi: 10.1126/scitranslmed.aan4488.

4.

S101, an Inhibitor of Proliferating T Cells, Rescues Mice From Superantigen-Induced Shock.

Shir A, Klein S, Sagiv-Barfi I, Geiger T, Zigler M, Langut Y, Edinger N, Levitzki A.

J Infect Dis. 2018 Jan 4;217(2):288-297. doi: 10.1093/infdis/jix576.

PMID:
29149330
5.

Holbrook Kohrt: In Memoriam (1977-2016).

Houot R, Pachynski R, Czerwinski DK, Goldstein MJ, Sagiv-Barfi I, Brody J, Müller AM, Marabelle A.

Clin Cancer Res. 2016 Jul 15;22(14):3695-6. doi: 10.1158/1078-0432.CCR-16-1181. No abstract available.

6.

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.

Sagiv-Barfi I, Kohrt HE, Czerwinski DK, Ng PP, Chang BY, Levy R.

Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):E966-72. doi: 10.1073/pnas.1500712112. Epub 2015 Feb 17.

7.

Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma.

Sagiv-Barfi I, Kohrt HE, Burckhardt L, Czerwinski DK, Levy R.

Blood. 2015 Mar 26;125(13):2079-86. doi: 10.1182/blood-2014-08-593137. Epub 2015 Feb 6.

8.

Radiotherapy and toll-like receptor agonists.

Marabelle A, Filatenkov A, Sagiv-Barfi I, Kohrt H.

Semin Radiat Oncol. 2015 Jan;25(1):34-9. doi: 10.1016/j.semradonc.2014.07.006. Review.

PMID:
25481264
9.

Targeting CD137 enhances the efficacy of cetuximab.

Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R, Troutner E, Richards L, Rajapaska A, Hebb J, Chester C, Waller E, Ostashko A, Weng WK, Chen L, Czerwinski D, Fu YX, Sunwoo J, Levy R.

J Clin Invest. 2014 Jun;124(6):2668-82. doi: 10.1172/JCI73014. Epub 2014 May 16.

10.

Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.

Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C, Zhang X, Buggy JJ, Muthusamy N, Levy R, Johnson AJ, Byrd JC.

Blood. 2014 Mar 20;123(12):1957-60. doi: 10.1182/blood-2014-01-547869. No abstract available.

11.

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.

Kohrt HE, Thielens A, Marabelle A, Sagiv-Barfi I, Sola C, Chanuc F, Fuseri N, Bonnafous C, Czerwinski D, Rajapaksa A, Waller E, Ugolini S, Vivier E, Romagné F, Levy R, Bléry M, André P.

Blood. 2014 Jan 30;123(5):678-86. doi: 10.1182/blood-2013-08-519199. Epub 2013 Dec 10.

12.

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.

Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, Luong R, Rosenblum MD, Steinman L, Levitsky HI, Tse V, Levy R.

J Clin Invest. 2013 Jun;123(6):2447-63. Erratum in: J Clin Invest. 2013 Nov;123(11):4980.

13.

Design, synthesis, and evaluation of quinazoline T cell proliferation inhibitors.

Sagiv-Barfi I, Weiss E, Levitzki A.

Bioorg Med Chem. 2010 Sep 1;18(17):6404-13. doi: 10.1016/j.bmc.2010.07.004. Epub 2010 Jul 8.

PMID:
20674367

Supplemental Content

Loading ...
Support Center